National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 1) (No. PB 4 of 2014)

Overview

The National Health (Highly Specialised Drugs Program for Hospitals) Special Arrangement Amendment Instrument 2014 (No. 1) was enacted to amend the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010, specifically updating the special arrangement related to the highly specialised drugs program for hospitals. The National Health Act 1953 empowers the Minister to make such special arrangements for the supply of pharmaceutical benefits, and this amendment instrument was made under the authority of subsections 100(1) and 100(2) of the Act. The policy objective of this amendment is to ensure that the highly specialised drugs program for hospitals remains aligned with current clinical and cost-effectiveness standards, as recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). The changes made by this instrument reflect updates to the National Health (Listing of Pharmaceutical Benefits) Instrument 2012, specifically addressing the circumstance codes and restriction text for all brands and forms of the drug Pamidronic Acid, ensuring that the program remains effective and up-to-date.

Scope and Application

The National Health (Highly Specialised Drugs Program for Hospitals) Special Arrangement Amendment Instrument 2014 (No. 1) amends the National Health (Highly Specialised Drugs Program for Hospitals) Special Arrangement 2010. This legislation applies to the supply of highly specialised pharmaceutical benefits, specifically for the treatment of chronic conditions requiring specialised facilities, to patients receiving treatment in public or private hospitals. The amendment relates to the drug Pamidronic Acid, updating the circumstance codes and the restriction text to reflect changes in the National Health (Listing of Pharmaceutical Benefits) Instrument 2012. This amendment ensures alignment with the updated pharmaceutical benefits listing, which is effective from the same date as the instrument's commencement. The instrument is applicable nationally, given its basis in the Commonwealth's National Health Act 1953, and does not specify exclusions or thresholds within the amendment itself. However, the overarching Act may include provisions for exclusions or exemptions which would apply in general terms. The instrument is a legislative instrument under the Legislative Instruments Act 2003 and commenced on 1 February 2014.

Key Provisions

The National Health (Highly Specialised Drugs Program for Hospitals) Special Arrangement Amendment Instrument 2014 (No. 1) amends the National Health (Highly Specialised Drugs Program for Hospitals) Special Arrangement 2010. The primary sections affected are those that relate to the supply of highly specialised drugs to hospitals under the National Health Act 1953. Specifically, the instrument updates the listing for the drug Pamidronic Acid (section 3(3) of Schedule 1). It replaces the existing circumstance codes and revises the restriction text for all brands and forms of Pamidronic Acid, aligning them with changes in the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (section 3(7) of Schedule 1). The Act imposes several obligations on the parties involved in the highly specialised drugs program for hospitals. Firstly, the Minister is required to make special arrangements for the supply of pharmaceutical benefits under section 100(1) of the Act. These special arrangements must reflect changes to the National Health (Listing of Pharmaceutical Benefits) Instrument, as seen in the amendment of Pamidronic Acid listings. Secondly, the Pharmaceutical Benefits Advisory Committee (PBAC) plays a crucial role in recommending changes to the special arrangement, ensuring that the drugs listed are clinically effective, safe, and cost-effective. The Act mandates that PBAC includes representatives from various healthcare-related fields, as outlined in section 100A. Pharmaceutical companies must also engage in consultations with PBAC and agree to the final listing details before the changes are implemented. The Act does not explicitly outline specific offences or penalties for breaches related to this special arrangement. However, non-compliance with the special arrangements or failure to adhere to the recommendations of PBAC could potentially lead to administrative actions or legal challenges. Given the nature of the Act and its focus on public health, any significant non-compliance might result in corrective measures, such as adjustments to funding or changes in drug supply arrangements, although formal penalties are not detailed within the legislative text. It is also important to note that the legislative instrument is subject to the oversight and enforcement mechanisms outlined in the Legislative Instruments Act 2003.